Autologous CAR-T Cell Manufacturing: Current Standing and Future Directions
A Look at What Drug Manufacturers are Likely Using to Make CAR-T Products
Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
For full access to this article login to GEN Select now.
Biomarket Trends: Shape of RNAi Screening Is Changing Rapidly
Thoroughness Requires Incorporation of More Than Just mRNA Assays
- In 2006, revenues in the total RNAi market amounted to approximately $85.1 million. Revenues were generated from the sales of content, delivery tools, and screening and analysis tools. Sales of content are expected to contribute the largest source of revenue to the total RNAi market through 2012. However, as ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.